Taysha Gene Therapies (TSHA) Other Non Operating Income (2022 - 2026)

Taysha Gene Therapies has reported Other Non Operating Income for 5 years, with the latest figure at -$31000.0 in Q1 2026.

• Quarterly Other Non Operating Income fell 338.46% year-over-year to -$31000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $941000.0 (up 563.55% YoY) and the FY2025 annual result came in at $1.2 million, up 1190.0% from the prior year.
• Other Non Operating Income declined to -$31000.0 in Q1 2026 per TSHA's latest filing, from $736000.0 in the prior quarter.
• Over five years, Other Non Operating Income peaked at $100.5 million in Q3 2023 and troughed at -$177000.0 in Q4 2024.
• A 5-year average of $8.5 million and a median of $1000.0 in 2022 frame the typical range for Other Non Operating Income.
• The sharpest annual moves came in 2023 and 2026: Other Non Operating Income surged 10045700.0% in 2023, then tumbled 338.46% in 2026.
• Over 5 years, Other Non Operating Income stood at -$6000.0 in 2022, then surged by 579133.33% to $34.7 million in 2023, then slumped by 100.51% to -$177000.0 in 2024, then jumped by 515.82% to $736000.0 in 2025, then tumbled by 104.21% to -$31000.0 in 2026.
• According to Business Quant data, Other Non Operating Income over the past three periods registered -$31000.0, $736000.0, and -$37000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.